Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Mirum Pharmaceuticals, Inc. - common stock
(NQ:
MIRM
)
68.48
-3.05 (-4.26%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mirum Pharmaceuticals, Inc. - common stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026
↗
December 03, 2025
Mirum Pharmaceuticals is a mid-cap biotech stock to keep your eyes on.
Via
The Motley Fool
Topics
Earnings
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake?
↗
December 02, 2025
A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next.
Via
The Motley Fool
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
December 01, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup
↗
November 29, 2025
Discover MIRM stock: A high-growth biotech with accelerating earnings, strong revenue, and a bullish technical setup poised for a potential breakout.
Via
Chartmill
Earnings Scheduled For November 4, 2025
↗
November 04, 2025
Via
Benzinga
Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45%
↗
November 27, 2025
Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm just made it a new position.
Via
The Motley Fool
Topics
Regulatory Compliance
Why This Private Equity-Style Fund Just Bet $17 Million on Lumen Technologies Stock
↗
November 27, 2025
One small-cap specialist just made a surprisingly large bet on one of telecom’s most complicated turnarounds.
Via
The Motley Fool
Penn Capital Unwinds $17.1 Million BGC Stake as Broker Posts 31% Revenue Surge
↗
November 27, 2025
This private-equity-style shop trimmed its position in a financial technology firm that's posting record numbers despite a steep stock decline.
Via
The Motley Fool
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
November 25, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®
November 07, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
What Analysts Are Saying About Mirum Pharmaceuticals Stock
↗
November 05, 2025
Via
Benzinga
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
November 04, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
November 03, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
October 28, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Presents a Compelling Growth Momentum and Technical Setup
↗
October 18, 2025
Mirum Pharmaceuticals (MIRM) shows strong revenue growth and a positive technical setup, presenting a compelling case for momentum investors seeking breakout opportunities.
Via
Chartmill
8 Analysts Assess Mirum Pharmaceuticals: What You Need To Know
↗
October 16, 2025
Via
Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Combines Strong Growth Momentum with Bullish Technical Setup
↗
September 27, 2025
Mirum Pharmaceuticals (MIRM) shows strong growth momentum with accelerating revenue and earnings, combined with a top-rated technical setup suggesting a potential breakout.
Via
Chartmill
This Riot Platforms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
↗
September 24, 2025
Via
Benzinga
Demystifying Mirum Pharmaceuticals: Insights From 6 Analyst Reviews
↗
September 12, 2025
Via
Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study
September 08, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows High Growth Momentum and Technical Breakout Potential
↗
September 05, 2025
Mirum Pharmaceuticals (MIRM) shows strong growth momentum with 62% revenue growth and a bullish technical breakout pattern, making it a top biotech stock to watch.
Via
Chartmill
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Screens as a High-Growth Momentum Stock Using Minervini Trend Template
↗
August 30, 2025
MIRUM Pharmaceuticals (MIRM) is a high-growth stock exhibiting a strong technical uptrend and robust revenue growth, making it a standout candidate for momentum investors.
Via
Chartmill
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
August 27, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Deep Dive Into Mirum Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
↗
August 08, 2025
Via
Benzinga
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Surpasses Q2 2025 Estimates with Strong Revenue Growth and Raised Guidance
↗
August 06, 2025
Mirum Pharmaceuticals beats Q2 2025 estimates with $127.8M revenue, narrows losses, and raises full-year guidance. Stock surges 8.6% post-earnings.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
August 06, 2025
Via
Benzinga
Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
August 06, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
